Metastatic prostate carcinoma
Therapeutic area
Oncology
Rare disease
No
- Definition
- A carcinoma that arises from the prostate gland and has spread to other anatomic sites.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Metastatic prostate carcinoma
- Therapeutic area
- Oncology
- metastatic prostate carcinoma
- metastatic prostate cancer
- metastatic prostate carcinoma
- prostate cancer metastatic
- prostate carcinoma metastatic
- Severity
- Terminal
- Oncology
- Reproductive Health
- MONDO ID
- MONDO:0004956
- Parent condition
- MONDO:0005159
Related records
Broader conditions (20)
- Cancer
- Cancer or benign tumor
- Carcinoma
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Epithelial neoplasm
- Human disease
- Male reproductive organ cancer
- Male reproductive system disorder
- Male reproductive system neoplasm
- Neoplasm
- Neoplastic disease or syndrome
- Prostate cancer
- Prostate carcinoma
- Prostate disorder
- Prostate neoplasm
- Reproductive system cancer
- Reproductive system disorder
- Reproductive system neoplasm
Trials (372)
- [18F]FLOR (FC303) PET/CT Imaging in Patients With Prostate Cancer
- [18F]Fluorthanatrace - Positron Emission Tomography (FTT-PET) and ctDNA to Predict Response to PARP Inhibitor Therapy in Metastatic Prostate Cancer (mPC)
- [68Ga]Ga-P17-079 in the Diagnosis and Treatment of Metastatic Prostate Cancer
- 11C-YJH08 PET Imaging for Detection of Glucocorticoid Receptor Expression
- 177Lu-DOTA-TLX591 Safety, Biodistribution and Dosimetry Study
- 177Lu-HTK03170 in mCRPC With PSMA Positive Disease
- 177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
- 177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer
- 177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer
- 18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer
- 18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer
- 18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer
- 18F-PSMA PET/CT Versus CT Alone in Assessment of Prostatic Cancer Patients
- 64Cu-TLX592 Phase I Safety, PK, Biodistribution and Dosimetry Study (CUPID Study)
- 68Ga PSMA-11 PET/CT in Recurrent Prostate Cancer
- 68Ga-P15-041 and 68Ga-PSMA-11 PET/CT Imaging in the Same Group of Prostate Bone Metastasis
- 68Ga-PSMA PET/CT for Ra223 Assessment
- 68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer
- 68Ga-PSMA-11 PET/CT for the Diagnosis of Bone Metastases in Patients With Prostate Cancer and Biochemical Progression During Androgen Deprivation Therapy
- 68GA-PSMA-11 PET/CT Scan in Impacting Treatment Strategies for Patients With Prostate Cancer
Approved drugs (15)
- Abiraterone acetate
- Apalutamide
- Cabazitaxel
- Darolutamide
- Docetaxel
- Enzalutamide
- Fluciclovine F18
- Flutamide
- Leuprolide acetate
- Nilutamide
- Piflufolastat F18
- Radium RA 223 dichloride
- Relugolix
- Triptorelin pamoate
- Zoledronic acid
Drugs in development (100)
- Abemaciclib Phase 1
- Abiraterone Phase 3
- Antineoplaston A10 Phase 2
- Ascorbic acid Phase 2
- Atezolizumab Phase 3
- Atorvastatin Phase 3
- Avelumab Phase 1
- AZD-8186 Phase 1
- Bavdegalutamide Phase 1
- Berzosertib Phase 2
- Bevacizumab Phase 3
- Bicalutamide Phase 3
- Bintrafusp alfa Phase 1
- Buserelin acetate Phase 1
- Carboplatin Phase 2
- Cediranib Phase 2
- CEP-11981 Phase 2
- Cisplatin Phase 2
- Creatine Phase 3
- Cyclophosphamide Phase 2